Biomedical Engineering Reference
In-Depth Information
[140]
Mora, A.L., Lavoy, J., McKean, M. et al., Prevention of NF-{kappa}B activation
in
vivo
by a cell permeable NF-{kappa}B inhibitor peptide,
Am. J. Physiol. Lung Cell
Mol. Physiol.
, 289, L536-544, 2005
.
[141]
Adams, G., Vessillier, S., Dreja, H. et al., Targeting cytokines to inflammation sites,
Nat. Biotechnol.,
21, 1314, 2003.
[142]
Li, Q. and Verma, I.M., NF-kappaB regulation in the immune system,
Nat. Rev.
Immunol.,
2, 725, 2002.
[143]
Karin, M., Yamamoto, Y., and Wang, Q.M., The IKK NF-kappaB system: A treasure
trove for drug development,
Nat. Rev. Drug Discov.,
3, 17, 2004.
[144]
Tergaonkar, V., Bottero, V., Ikawa, M. et al., IkappaB kinase-independent IkappaBal-
pha degradation pathway: Functional NF-kappaB activity and implications for cancer
therapy,
Mol. Cell. Biol.,
23, 8070, 2003.
[145]
Ryan, K.M., Ernst, M.K., Rice, N.R. et al., Role of NF-kappaB in p53-mediated
programmed cell death,
Nature,
404, 892, 2000.
[146]
Kato, T., Jr., Delhase, M., Hoffmann, A. et al., CK2 is a C-terminal IkappaB kinase
responsible for NF-kappaB activation during the UV response,
Mol. Cell,
12, 829,
2003.
[147]
Panta, G.R., Kaur, S., Cavin, L.G. et al., ATM and the catalytic subunit of DNA-
dependent protein kinase activate NF-kappaB through a common MEK/extracellular
signal-regulated kinase/p90(rsk) signaling pathway in response to distinct forms of
DNA damage,
Mol. Cell. Biol.,
24, 1823, 2004.
[148]
Bohuslav, J., Chen, L.F., Kwon, H. et al., p53 induces NF-kappaB activation by an
IkappaB kinase-independent mechanism involving phosphorylation of p65 by ribo-
somal S6 kinase 1,
J. Biol. Chem.,
279, 26115, 2004.
[149]
May, M.J., Marienfeld, R.B., and Ghosh, S., Characterization of the IkappaB-kinase
NEMO binding domain,
J. Biol. Chem.,
277, 45992, 2002.
[150]
May, M.J., D'Acquisto, F., Madge, L.A. et al., Selective inhibition of NF-kappaB
activation by a peptide that blocks the interaction of NEMO with the IkappaB kinase
complex,
Science,
289, 1550, 2000.
[151]
Thomas, R.P., Farrow, B.J., Kim, S. et al., Selective targeting of the nuclear factor-
kappaB pathway enhances tumor necrosis factor-related apoptosis-inducing ligand-
mediated pancreatic cancer cell death,
Surgery,
132, 127, 2002.
[152]
Dasgupta, S., Jana, M., Zhou, Y. et al., Antineuroinflammatory effect of NF-kappaB
essential modifier-binding domain peptides in the adoptive transfer model of exper-
imental allergic encephalomyelitis,
J. Immunol.,
173, 1344, 2004.
[153]
Choi, M., Rolle, S., Wellner, M. et al., Inhibition of NF-kappaB by a TAT-NEMO-
binding domain peptide accelerates constitutive apoptosis and abrogates LPS-delayed
neutrophil apoptosis,
Blood,
102, 2259, 2003.
[154]
Dai, S., Hirayama, T., Abbas, S. et al., The IkappaB kinase (IKK) inhibitor, NEMO-
binding domain peptide, blocks osteoclastogenesis and bone erosion in inflammatory
arthritis,
J. Biol. Chem.,
279, 37219, 2004.
[155]
Ankermann, T., Reisner, A., Wiemann, T. et al., Topical inhibition of nuclear factor-
kappaB enhances reduction in lung edema by surfactant in a piglet model of airway
lavage,
Crit. Care Med.,
33, 1384, 2005.
[156]
Rehman, K.K., Bertera, S., Bottino, R. et al., Protection of islets by in situ peptide-
mediated transduction of the IkappaB kinase inhibitor NEMO-binding domain pep-
tide,
J. Biol. Chem.,
278, 9862, 2003.
[157]
Horng, T., Barton, G.M., and Medzhitov, R., TIRAP: An adapter molecule in the Toll
signaling pathway,
Nat. Immunol.,
2, 835, 2001.
